The conventional frame attributes inadequate pain management in the developing world to drug access problems — opioids are scarce, expensive, or culturally stigmatized. The structural lens identifies a channel architecture problem: the same regulatory channel that controls opioid diversion also controls opioid access for legitimate pain treatment. Tightening the channel against diversion simultaneously tightens it against patients in pain. The two functions — preventing abuse and enabling treatment — travel the same pipe, and optimizing for one degrades the other. The collision partners are telecommunications engineers (who solved the same problem — multiple signals in one channel — through multiplexing, separating the signals within the shared medium) and dual-use technology regulators who manage analogous two-function-one-channel problems.
A woman in rural Uganda is dying of cervical cancer. The pain is total — bone metastases, nerve compression, soft tissue invasion. She has weeks to live. The medication that would give her comfort exists. Oral morphine costs approximately four cents per dose. The factory that produces it is on the same continent.
She will die in agony. Not because the medication is expensive. Not because the knowledge is lacking. Not because the delivery infrastructure is absent. Because the international regulatory system that controls opioids was designed to prevent a DIFFERENT problem — addiction in wealthy countries — and the system makes no distinction between preventing misuse and preventing access. The same pipe carries both regulations. The pipe is built for one purpose. It is producing two effects.
Eighty percent of the world’s population has inadequate access to pain management. Not “suboptimal.” INADEQUATE. Millions of people die each year in unnecessary pain because the regulations designed to prevent addiction in one context prevent relief in another.
The Lancet Commission on Palliative Care and Pain Relief called this a “global crisis of untreated pain.” The WHO has issued guidelines. Advocacy organizations have worked for decades. The barriers are documented: regulatory restrictions on opioid prescribing and distribution (particularly in low- and middle-income countries), limited training in palliative care, cultural and professional attitudes that conflate pain treatment with addiction risk, and supply chain failures for essential pain medications.
The regulatory barrier is the most structurally intractable. International narcotics conventions — the Single Convention on Narcotic Drugs (1961) and its successors — require countries to control opioid substances. Many countries implemented controls that are far more restrictive than the conventions require — in some cases making it effectively impossible for a physician to prescribe morphine for any reason. The overcorrection is staggering.
The advocacy frame: “relax the restrictions.” The political response: relaxing opioid restrictions is politically impossible in an era of opioid crisis in wealthy countries.
The regulatory system is managing two DIFFERENT problems through ONE channel.
Problem 1: Preventing opioid misuse and addiction. Real problem. Significant consequences. Requires regulation of access to prevent non-medical use.
Problem 2: Ensuring access to pain management for people who need it. Real problem. Far larger in scale (the 80% without access vastly outnumbers the addiction-affected population). Requires facilitation of access for medical use.
The two problems require OPPOSITE regulatory actions applied to the SAME substance. Problem 1 requires restriction. Problem 2 requires facilitation. The current system applies Problem 1’s solution uniformly, which solves Problem 1 (in the jurisdictions where it’s enforced) and creates Problem 2 (in every jurisdiction where access is needed).
In access control engineering — cybersecurity, building security, information systems — this is a solved problem. Access control systems routinely provide different levels of access to the same resource based on context. A hospital’s drug cabinet provides access to authorized personnel (physicians, pharmacists) while denying access to unauthorized personnel. The substance is the same. The access rules differ based on role, context, and authorization. The system DISTINGUISHES.
The international opioid control system does not distinguish. It applies one rule — restrict — to all contexts. A physician in Uganda trying to prescribe morphine for a dying cancer patient faces regulatory barriers designed for a street dealer in a wealthy country. The CONTEXT is different. The RULES are the same.
The design question: how do you build a regulatory system that restricts access in contexts where restriction is needed AND facilitates access in contexts where facilitation is needed, applied to the same substance?
This is an access control design problem. It has been solved in every other domain where a resource must be simultaneously controlled and distributed.
| Factor | Score | Justification |
|---|---|---|
| F1: Mortality & Irreversibility | 8 | Millions die in preventable pain; death in agony when relief is available is among the most extreme failures of organized society |
| F2: Scale | 9 | 80% of the world’s population — billions of people |
| F3: Compression Depth | 9 | Unmanaged pain at end of life is total compression — consciousness reduced to a single dimension of suffering |
| F4: Time Sensitivity | 7 | People are dying in pain today; each day of inaction is more preventable suffering |
| F5: Voice Deficit | 8 | The affected populations are in low-income countries with limited international advocacy power |
| F6: Proximity Gap | 7 | Access control engineers and cybersecurity specialists are not in the narcotics regulatory conversation |
| F7: Temporal Displacement | 2 | The suffering is immediate |
| F8: Normalization | 6 | “Opioids are dangerous” normalizes restriction without distinguishing context |
| F9: Hallway Dependency | 7 | The two-channel design requires access control engineering + palliative care + international drug policy |
| F10: Knowledge Readiness | 8 | Palliative care protocols exist; morphine production is simple; access control design is mature |
| F11: Entry Cost | 5 | International regulatory reform is politically expensive; national-level reforms are feasible |
| F12: Cascade Potential | 7 | The two-channel design applies to any substance that must be simultaneously controlled and distributed |
Hiddenness Score: 48.3 Actionability Score: 53
Access control engineers in cybersecurity design systems that provide differentiated access to the same resource based on context. The specific transferable knowledge: role-based access control (different users get different permissions), context-aware authentication (the same user gets different access depending on where, when, and why they’re requesting it), and audit trails (every access event is logged, enabling after-the-fact review without blocking legitimate use in real time). Applied to opioid regulation: a physician in a palliative care context receives facilitated access. A non-medical context receives restricted access. Both are managed. Both use the same substance. The system DISTINGUISHES.
Water management engineers manage the same resource for different purposes through different channels with different controls. Irrigation water, drinking water, and industrial water come from the same source but are distributed through different channels with different quality standards, different access rules, and different pricing. The substance is the same. The management is differentiated. The specific transferable knowledge: you don’t manage a resource with a single rule when the resource serves multiple purposes. You differentiate.
If you are a palliative care physician in a country with restrictive opioid regulations: document the SPECIFIC regulatory barriers you face. Not “regulations are too strict” — the specific form, the specific approval process, the specific delay. The documentation converts the barrier from a complaint into an engineering specification: HERE is where the access control system fails for legitimate medical use. The specification is what the redesign needs.
If you are a policy designer: commission an access control analysis of your country’s opioid regulatory system. Ask: does this system distinguish between the contexts where restriction is needed and the contexts where facilitation is needed? If it applies one rule to all contexts, it is a single-channel system managing a two-channel problem. The redesign begins with the distinction.